Site search
2879 results for '' found
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance ther
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance ther
/
The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of car
The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of car
/
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma (NCT06376045)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma (NCT06376045)
/
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Pr
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Pr
/
Assessment of MEchaNical Dyssynchrony versus standard selection on clinical response in candidates for Cardiac Resynchronization Therapy – The AMEND-CRT Trial (NCT04225520)
Assessment of MEchaNical Dyssynchrony versus standard selection on clinical response in candidates for Cardiac Resynchronization Therapy – The AMEND-CRT Trial (NCT04225520)
/
Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial (ACTRN12622001366741)
Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial (ACTRN12622001366741)
/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis [NASH]/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis [NASH]/
/
A Phase 3, Randomized, Double-blind, Placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH) and fibrosis. (
A Phase 3, Randomized, Double-blind, Placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH) and fibrosis. (
/
A Phase II observational study: autologous haematopoietic stem cell transplantation for highly active treatment resistant multiple sclerosis (ACTRN12616000151437)
A Phase II observational study: autologous haematopoietic stem cell transplantation for highly active treatment resistant multiple sclerosis (ACTRN12616000151437)
/